This is an open-label, dose-escalation phase I study to assess the safety and tolerability of siCoV/KK46 in healthy volunteers. The purpose of this study is to determine the maximum daily dose of siCoV/KK46 as a single agent in adult healthy participants. Based on preclinical data from this institution, the investigators hypothesize that SARS-CoV-2 inhibition with siCoV/KK46 could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.
This is an open-label, dose-escalation phase I study to assess the safety and tolerability of single and multiple doses of siCoV/KK46 in healthy male volunteers. This study include 3 cohorts received 3.7 mg, 11.1 mg, 22.2 mg of the siCoV/KK46, respectively, via inhalation route. All subjects will undergo scheduled safety and tolerability assessments while in the clinical unit and as outpatients to the end of the follow-up period.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
The modified phase I "3 + 1+1" study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg.
NRC Institute of Immunology FMBA
Moscow, Russia
This is an open-label, dose-escalation phase I study to assess the safety and tolerability of siCoV/KK46 in healthy volunteers
Adverse Events
Time frame: Within 72 hours after single treatment with siCoV/KK46
Vital Signs
Blood pressure in mm Hg
Time frame: Within 72 hours after single treatment with siCoV/KK46
Body Temperature control
Taking an Axillary Temperature
Time frame: Within 72 hours after single treatment with siCoV/KK46
Heart rate
Heart Rate in beats per minute
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Potassium level
Measurement of Potassium level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Sodium level
Measurement of Sodium level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Chloride level
Measurement of Chloride level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Bicarbonate level
Measurement of Bicarbonate level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Calcium level
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Measurement of Calcium level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Phosphate level
Measurement of Phosphate level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Creatine phosphokinase level
Measurement of Creatine phosphokinase level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Blood urea nitrogen level
Measurement of Blood urea nitrogen level
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Albumin level
Measurement of Albumin level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Protein level
Measurement of Protein level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Aspartate transaminase level
Measurement of Aspartate transaminase level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Alanine transaminase level
Measurement of Alanine transaminase level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Alkaline phosphatase level
Measurement of Alkaline phosphatase level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Clinical Chemistry to asses Bilirubin level
Measurement of Bilirubin level in blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Blood Glucose Test
Measurement of Glucose level
Time frame: Within 72 hours after single treatment with siCoV/KK46
Haematology blood test
Qualitative and quantitative composition of the cellular components of the blood
Time frame: Within 72 hours after single treatment with siCoV/KK46
Urinalysis
Physical, chemical, and microscopic examination of urine
Time frame: Within 72 hours after single treatment with siCoV/KK46
12-Lead Electrocardiogram
Measurement of Heart rate; PR, QRS, RR, QT and QTc intervals from digital recordings
Time frame: Within 72 hours after single treatment with siCoV/KK46